CAMBRIDGE, Mass., Feb. 19, 2019 /PRNewswire/ -- Blueprint Medicines
Corporation (NASDAQ: BPMC), a precision therapy company focused on
genomically defined cancers, rare diseases and cancer
immunotherapy, today announced that it will host a live
conference call and webcast at 8:30 a.m. ET on Tuesday, February 26, 2019 to report its fourth
quarter and full year 2018 financial results and provide a
corporate update.
To access the live conference call, please dial (855) 728-4793
(domestic) or (503) 343-6666 (international), and refer to
conference ID 26735762. A webcast of the call will also be
available under "Events and Presentations" in the Investors &
Media section of Blueprint Medicines' website at
http://ir.blueprintmedicines.com/. The archived webcast will be
available on Blueprint Medicines' website approximately two hours
after the conference call and will be available for 30 days
following the call.
About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving
to improve human health. With a focus on genomically defined
cancers, rare diseases and cancer immunotherapy, we are developing
transformational medicines rooted in our leading expertise in
protein kinases, which are proven drivers of disease. Our uniquely
targeted, scalable approach empowers the rapid design and
development of new treatments and increases the likelihood of
clinical success. We are currently advancing four investigational
medicines in clinical development, along with multiple research
programs. For more information,
visit www.BlueprintMedicines.com and follow us
on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-fourth-quarter-and-full-year-2018-financial-results-on-tuesday-february-26-2019-300796794.html
SOURCE Blueprint Medicines